Effect of montelukast for treatment of asthma in cigarette smokers

The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis

“…Current-smoking asthmatics have less eosinophils and more neutrophils in their sputum and blood than never-smoking asthmatics [32], which are similar characteristics to COPD patients. A recent randomized controlled study showed that montelukast significantly increased the mean percentage of days with asthma control in a population of asthmatic patients actively smoking cigarettes [33]. In addition, airway inflammatory features during exacerbation in asthma and COPD are similar, and it was reported that Cys-LT1 receptor expression increased in the bronchial mucosa of patients with severe exacerbation of COPD [34].…”

Smoking asthma phenotype

“…These findings demonstrate a different effect of smoking in arachidonic acid metabolism in asthma and suggest that targeting specific lipoxygenase and cyclooxygenase pathways activated by asthma and by tobacco smoking may optimize therapeutic responses [37 & ]. A large, randomized, double-blind, parallelgroup study evaluated the efficacy and safety of montelukast (10 mg once daily) and high-dose inhaled fluticasone (250 mg twice daily) compared with placebo in smoking asthmatic patients [38]. Over a 6-month period, patients in both the fluticasone and montelukast treatment arms demonstrated significantly more days of asthma control and significant improvement in the mean daytime symptom score change from baseline.…”

Current Administration of Antileukotrienes in Adults With Asthma

“…Опти-мальная терапия для таких больных не разработана, но предварительные данные позволяют предполо-жить, что антагонисты LT-рецепторов могут оказы-вать положительный эффект у курильщиков с БА легкой степени [34]. По данным исследования, в ко-тором сравнивалась эффективность флутиказона 500 мкг в сутки, монтелукаста 10 мг в сутки и плацебо у активных курильщиков с БА, при использовании флутиказона более эффективно, чем при использова-нии монтелукаста контролировалось течение заболе-вания при анамнезе курения ≤ 11 пачко-лет, и, на-оборот, монтелукаст был эффективнее флутиказона при анамнезе курения > 11 пачко-лет [35].…”